Jean Mah
Principal Applicant
Pediatrics and Clinical Neurosciences Professor at the Cumming School of Medicine
Pediatric Neurologist and the Director of the Pediatric Neuromuscular Program at the Alberta Children’s Hospital
NMD4C Involvement: Pillar 2: Clinical Research, Theme 5: Open Science
Biography
Dr. Jean Mah is a pediatric neurologist and the director of the Pediatric Neuromuscular Program at the Alberta Children’s Hospital in Calgary, Alberta, Canada. She is a Professor of Pediatrics and Clinical Neurosciences at the Cumming School of Medicine, University of Calgary. She is currently involved in multicenter clinical research studies related to pediatric neuromuscular diseases.
Recent Publications
Mercuri, E, Vilchez, JJ, Boespflug-Tanguy, O, Zaidman, CM, Mah, JK, Goemans, N et al.. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024.23 (4)393-403 PMID:38508835
Dang, UJ, Damsker, JM, Guglieri, M, Clemens, PR, Perlman, SJ, Smith, EC et al.. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial. Neurology. 2024.102 (5)e208112 PMID:38335499
Price, TR, Hodgkinson, V, Westbury, G, Korngut, L, Innes, MA, Marshall, CR et al.. A Study on the Incidence and Prevalence of 5q Spinal Muscular Atrophy in Canada Using Multiple Data Sources. Can J Neurol Sci. 2024. 1-12 PMID:38178730
Niri, F, Nicholls, J, Baptista Wyatt, K, Walker, C, Price, T, Kelln, R et al.. Alberta Spinal Muscular Atrophy Newborn Screening-Results from Year 1 Pilot Project. Int J Neonatal Screen. 2023.9 (3) PMID:37606479
Clemens, PR, Rao, VK, Connolly, AM, Harper, AD, Mah, JK, McDonald, CM et al.. Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study. J Neuromuscul Dis. 2023.10 (3)439-447 PMID:37005891
Sherlock, SP, Palmer, J, Wagner, KR, Abdel-Hamid, HZ, Tian, C, Mah, JK et al.. Dual-energy X-ray absorptiometry measures of lean body mass as a biomarker for progression in boys with Duchenne muscular dystrophy. Sci Rep. 2022.12 (1)18762 PMID:36335191
Pacaud, D, Romanchuk, KG, Virtanen, H, Ferdousi, M, Nettel-Aguirre, A, Mah, JK et al.. Corneal nerve and nerve conduction abnormalities in children with type 1 diabetes. Pediatr Diabetes. 2022.23 (8)1665-1673 PMID:36131228
Katz, SL, Blinder, H, Newhook, D, Bmus, LA, Nicholls, S, McMillan, HJ et al.. Understanding the experiences of lung volume recruitment among boys with Duchenne muscular dystrophy: A multicenter qualitative study. Pediatr Pulmonol. 2023.58 (1)46-54 PMID:36102618
Guglieri, M, Clemens, PR, Perlman, SJ, Smith, EC, Horrocks, I, Finkel, RS et al.. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA Neurol. 2022.79 (10)1005-1014 PMID:36036925
Muntoni, F, Guglieri, M, Mah, JK, Wagner, KR, Brandsema, JF, Butterfield, RJ et al.. Novel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD): Observations from a phase 2 trial. PLoS One. 2022.17 (8)e0272858 PMID:35998119
See more on PubMed